Healthcare Sector Update: Analysts Weigh in on Perspective Therapeutics, Axsome Therapeutics, and HCA Healthcare

Analysts at Bank of America Securities and Morgan Stanley have weighed in on Perspective Therapeutics, Axsome Therapeutics, and HCA Healthcare. Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Perspective Therapeutics with a $6.00 price target, while Morgan Stanley analyst Craig Hettenbach maintained a Hold rating on HCA Healthcare with a $355.00 price target. The analyst consensus on Perspective Therapeutics is a Strong Buy, while HCA Healthcare has a Moderate Buy rating.

The healthcare and biotech sectors have been under the spotlight lately, with several companies garnering attention from analysts. Among these are Perspective Therapeutics, Axsome Therapeutics, and HCA Healthcare. Let's take a closer look at the recent analyst ratings for these companies.

First, Perspective Therapeutics (PRTP) received a Hold rating from Alec Stranahan, an analyst at Bank of America Securities. The analyst set a $6.00 price target on the stock, which aligns with the current market price. The consensus among analysts is a Strong Buy, with an average price target of $13.31, indicating a potential upside of 115.6% [1].

Next, Axsome Therapeutics (AXSM) also received a Hold rating, this time from Craig Hettenbach at Morgan Stanley. Hettenbach set a $355.00 price target on the stock, which is slightly above the current market price. The consensus among analysts is a Moderate Buy, with an average price target of $404.79, indicating a potential upside of 145.5% [1].

Lastly, HCA Healthcare (HCA) received mixed signals from analysts. Bank of America Securities maintained a Hold rating on the stock, with a $355.00 price target, while Morgan Stanley upgraded its rating to Overweight and set a $400.00 price target [2]. The consensus among analysts is a Moderate Buy, with an average price target of $382.78, indicating a potential upside of 28.3% [1].

It's important to note that while analyst ratings can provide valuable insights, they should not be the sole basis for investment decisions. It's essential to conduct your own research and consider various factors before making any investment decisions.

References:
[1] Benzinga. (2024, May 10). Bank of America Corp (BAC) Stock Analysis. Retrieved May 11, 2024, from https://www.benzinga.com/quote/BAC/analyst-ratings
[2] Investor's Business Daily. (2024, May 11). Bank of America, Morgan Stanley Top Q4 Earnings. Retrieved May 11, 2024, from https://www.investors.com/news/bank-of-america-morgan-stanley-q4-2024-earnings-bac-stock-ms-stock/